| 摘要: |
| ［摘要］ 目的 观察玻璃体腔注射雷珠单抗治疗黄斑区脉络膜新生血管（choroidal neovascularization,CNV）的疗效及安全性。方法 对26例26眼经光学相干断层扫描（optical coherence tomography，OCT）及眼底血管荧光造影（fundus fluoresceine angiography，FFA）确诊为黄斑区CNV（包括年龄相关性黄斑变性、高度近视性黄斑病变以及中心性渗出性脉络膜视网膜病变）的患者进行玻璃体腔内注射0.5 mg/0.05 ml雷珠单抗，随访3个月，观察患者最佳矫正视力（best-corrected visual acuity，BCVA)、黄斑区结构改变及不良反应。在随访期间，经OCT检查发现黄斑区神经上皮层仍有层间积液或视网膜下液、CNV未见明显缩小、FFA检查发现仍有荧光素渗漏者需行再次注射雷珠单抗。结果 所有患者第一次治疗前BCVA（ETDRS字母表）的平均字母数为（17.65±13.96）个，3个月后的平均字母数为(34.23±16.36)个，3个月后与第一次治疗前的视力差异具有统计学意义（P<0.05）。所有患者第一次治疗前黄斑中心凹厚度（central macular thickness，CMT）为(310.84±113.13)μm，随访第3个月时为（198.76±46.90）μm，前后相比差异具有统计学意义（P<0.05）。术中、术后及随访期间未见眼部及全身不良反应。结论 玻璃体腔内注射雷珠单抗治疗黄斑区CNV安全有效。 |
| 关键词: 雷珠单抗 脉络膜新生血管 玻璃体腔注射 |
| DOI：10.3969/j.issn.1674-3806.2016.02.10 |
| 分类号:R 773.4 |
| 基金项目: |
|
| The efficacy of ranibizumab treatment in patients with macular choroidal neovascularization |
|
CHEN Li-fei, LI Min, WU Xue-jin
|
|
Department of Ophthalmology, the People′s Hospital of Guangxi Zhuang Autonomous Region, Nanning 530021, China
|
| Abstract: |
| ［Abstract］ Objective To evaluate the efficacy and safety of intravitreal injection of ranibizumab for macular choroidal neovascularization(CNV).Methods Twenty-six eyes of 26 patients diagnosed with macular choroidal neovascularization caused by age-related macular degeneration, high myopia macular degeneration and central exudative retinopathy were included in this study. Intravitreal injections of ranibizumab(0.5 mg/0.5 ml) were performed on all eyes. All patients were followed-up for 3 months, and the best-corrected visual acuity(BCVA), the central macular thickness(CMT) and complications were recorded.Results During the follow-up period, the mean of BCVA improved from (17.65±13.96) letters to (34.23±16.36) letters after a follow-up of 3 months(P<0.05); the mean of CMT decreased from (310.84±113.13)μm to （198.76±46.90）μm after a follow-up of 3 months（P<0.05）. Retinal detachment, endophthalmitis, lens injury and systemic adverse reactions were not found.Conclusion Intravitreal injection of ranibizumab is an effective and safe treatment for macular CNV. |
| Key words: Ranibizumab Choroidal neovascularization Intravitreal injection |
